期刊文献+

急诊经桡动脉冠脉介入治疗急性冠脉综合征中应用替罗非班的有效性和安全性 被引量:6

下载PDF
导出
摘要 目的评估盐酸替罗非班对急性冠脉综合征(ACS)患者急诊经皮冠状动脉介入治疗(PCI)时防治无复流现象的作用以及安全性。方法 116例ACS患者随机分为盐酸替罗非班组和对照组,观察两组PCI术后TIMI血流级别、24 h肌钙蛋白T(CTnT)水平、24 h及30 d复合心血管终点事件发生率及出血情况。结果替罗非班组和对照组PCI术后TIMI 3级血流发生率分别为96.8%和88.9%,TIMI 0~2级血流发生率分别为3.2%和11.1%,P均<0.05。替罗非班组24 h CTnT水平较对照组降低(P<0.05),主要复合终点心血管事件发生率较对照组降低(P<0.05)。两组均无严重出血事件发生。结论盐酸替罗非班能明显降低ACS患者PCI术后无复流现象的发生,并改善无复流现象程度。
出处 《山东医药》 CAS 2012年第16期77-79,共3页 Shandong Medical Journal
  • 相关文献

参考文献10

  • 1无.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2010,38(8):675-690. 被引量:1991
  • 2Kushner FG, Hand M, Smith SC Jr, et al. 2009 Focused Updates : ACC/AHA Guidelines for the Management of Patient With ST-Ele- vation Myocardial Infarction ( Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention ( Updating the 2005 Guideline and 2007 Fo- cused Update ) : A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [J]. J Am Coil Cardiol, 2009,54 (23) :2205-2241.
  • 3Kenner MD, Zajac EJ, Kondos GT, et al. Ability of the no-reflow phenomenon during an acute myocardial infarction to predict left ventricular dysfunction at one-month follow-up [ J ]. Am J Cardiol, 1995,76(12) :861-868.
  • 4Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicrandil can preserve microvascular integrity andmyocardial viability in patient s with reperfused anterior wall myocardial infarction [ J ]. J Am Coil Cardiol, 1999,33 ( 3 ) :654-660.
  • 5Kabbani SS, Aggarwal A, Terrien EF, et al. Subptimal early inhibi- tion of platelets by treatment with tirofiban and implications for coro- nary interventions [J]. Am J Cardiol, 2002,89(12) :647-651.
  • 6Shishehbor MH, Topoi EJ, Mukherjee D, et al. Outcome of mul- tivessel coronary intervention in the contemporary percutaneous re- vascularization era [ J ]. Am J Cardiol, 2006,97 ( 11 ) : 1585-1590.
  • 7Boztosun B, Gunes Y, Kirma C, et al. Successful lysis of coronary thrombi by long term warfarin treatment after a failed course of tirofi- ban infusion [Jl. Int J Cardiol, 2006,108(1) :114-116.
  • 8张宇晨,贾三庆,王雷,李虹伟,王永亮,王宇朋,赵林,姚道阔,丁荣晶.直接PCI术患者冠状动脉内注射替罗非班的安全性及其改善心肌灌注的研究[J].中国全科医学,2007,10(22):1876-1878. 被引量:10
  • 9Boersma E, Harrington RA, Moliterno D J, et al. Platelet glycopro- tein Ⅱ b/Ⅲa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials [ J ]. Lancet, 2002, 359 (9302) : 189-198.
  • 10Madan M, Radhakrishnan S, Reis M, et al. Comparison of enox- aparin versus heparin during elective percutaneous coronary inter- vention performed with either eptifibatide or tirofigan ( the ACTION trial) [J]. Am J Cardiol, 2005,95(11):1295-1301.

二级参考文献17

  • 1张燕,刘鹏,李靖.替罗非班对冠心病PCI术中内皮功能障碍影响的研究[J].中国误诊学杂志,2006,6(16):3069-3071. 被引量:8
  • 2Collaborative Research Group of Reperfusion Therapy in Acute Myocardial Infarction.重组葡激酶与重组组织型纤溶酶原激活剂治疗急性心肌梗死的随机多中心临床试验[J].中华心血管病杂志,2007,35(8):691-696. 被引量:43
  • 3Yang YJ,Zhao JL,You SJ,et al.Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-flow in a mini-swine model of acute myocardial infaction and reperfusion[J].Heart,2006,93:1131-1137.
  • 4Gibson CM,Cannon CP,Murphy SA,et al.Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs[J].Circulation,2000,101:125-130.
  • 5Michaels AD,Gibson CM,Barron HV.Microvascular dysfunction in acute myocardial infarction:focus on the roles of platelet and inflammatory mediators in the no -reflow phenomenon[J].Am J Cardiol,2000,85:50B -60B.
  • 6Brener SJ,Barr LA,Burchenal JE,et al.Randomized,placebocontrolled trial of platelet glycoprotein Ⅱ b/Ⅲ a blockade with primary PTCA Organization and Randomized Trial (RAPPORT)[J].Circulation,1998,98:734-741.
  • 7Montalescot G,Barragan P,Wittenberg O,et al.For the ADMIRAL Investigators.Platelet glycoprotein Ⅱ b/Ⅲ a inhibition with coronary stenting for acute myocardial infarction[J].N Eng J Med,2001,344:1895-1903.
  • 8Stone GW,Grines CL,Cox DA,et al.Comparision of angioplasty with stenting,with or without abciximab,in acuete myocardial infarction[J].N Eng J Med,2002,346:957-966.
  • 9Gibson CM,Christopher PC,William LD,et al.TIMI frame count:A quantitative method of assessing coronary artery flow[J].Circulation,1996,93:879-888.
  • 10Neumann FJ,Blasini R,Schmitt C,et al.Effect of glycoprotein Ⅱb/Ⅲ a receptor blockade on recovery flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infction[J].Circulation,1998,98:2695-2701.

共引文献1999

同被引文献52

  • 1孟宪刚,王莉.氯吡格雷抵抗对老年冠心病合并糖尿病患者冠脉介入治疗预后的影响及危险因素[J].中国老年学杂志,2014,34(9):2321-2322. 被引量:28
  • 2沈杰,沈卫峰.替罗非班在急性冠脉综合征介入治疗中的应用[J].国际心血管病杂志,2006,33(3):156-159. 被引量:72
  • 3杨新春,张大鹏,王乐丰,徐立,葛永贵,王红石,李惟铭,倪祝华,夏昆,连勇,薛永利,马利祥.冠状动脉内应用国产替罗非班对急性ST段抬高心肌梗死急诊介入治疗后心肌灌注和临床预后的影响[J].中华心血管病杂志,2007,35(6):517-522. 被引量:74
  • 4Warnholtz A,Ostad MA,Heitzer T,et al.Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease[J].Am J Cardiol,2005,95(1):20- 23.
  • 5Sakuma T,Leong-Poi H,Fisher NG,et al.Further insights into the no-reflow phenomenon after primary angioplasty in acute myocardial infarction: the role of microthromboemboli[J].J Am Soc Echocardiogr,2003, 16(1):15-21.
  • 6Porto I,Ashar V,Mitchell ARJ,et al.Pharmacological management of no reflow during percutaneous coronary intervention[J].Current Vascular Pharmacology,2006,4(3):95-100.
  • 7Wu TG,Zhao Q,Huang WG,et al.Effect ofintracoronary tirofiban in patients undergoingpercutaneous coronary intervention for acutecoronary syndrome[J].Circ J,2008,72(10): 1605-1609.
  • 8Friedland S, Eisenberg M J, Shimony A .Meta-analysis of randomized controlled trials ofintracoronary versus intravenous administration ofglycoprotein Ilb/IIIa inhibitors during percutaneouscoronary intervention for acute coronarysyndrome[J].Am J Cardiol,2011,108(9): 1244-1251.
  • 9Zhang Y,Gao C’Liu H,et al.Routine earlyversus deferred provisional tirofiban treatmentin patients with acute coronary syndromeundergoing percutaneous coronary intervention[J].Clin Exp Pharmacol Physiol,2013,40⑷:289-294.
  • 10Cruz-Gonzalez I,Sanchez-Ledesma M,BaronSJ,et al. Efficacy and safety of argatroban withor without glycoprotein llb/IIIa inhibitor inpatients with heparin induced thrombocytopeniaundergoing percutaneous coronary interventionfor acute coronary syndrome[J].J Thromb Thrombolysis,2008 ’ 25(2): 214-218.

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部